The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDeltex Medical Regulatory News (DEMG)

Share Price Information for Deltex Medical (DEMG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.125
Bid: 0.11
Ask: 0.14
Change: 0.00 (0.00%)
Spread: 0.03 (27.273%)
Open: 0.125
High: 0.125
Low: 0.125
Prev. Close: 0.125
DEMG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New Functionality on CardioQ-ODM+ Monitor Platform

4 May 2017 07:00

RNS Number : 1145E
Deltex Medical Group PLC
04 May 2017
 

 

4 May 2017

 

 

Deltex Medical Group plc

("Deltex Medical", "Deltex" or "the Company")

 

 

Deltex releases non-invasive High Definition Impedance Cardiography module on its CardioQ-ODM+ monitor platform

 

Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler Monitoring ("ODM"), announces the launch of non-invasive High Definition Impedance Cardiography (HD-ICG) in the UK, as an additional module on its CardioQ-ODM+ monitoring platform.

 

HD-ICG provides a continuous indirect measurement of central blood flow. An electrical field is set up across the patient's chest following placement of a single patient disposable set of sensors on the abdomen. The disruption to this field caused by the heart pumping blood is measured and used to calculate cardiac output variables using an established nomogram. The sensors are connected to the Deltex monitor via a small console which also powers the sensors and values are displayed on specially designed screens on the CardioQ-ODM+.

 

The HD-ICG system is non-invasive making it ideal for monitoring patients in both critical care and surgery who are awake and do not tolerate ODM probes. Adding it to the CardioQ-ODM+ increases the numbers of patients the Company can treat.

 

The Company is launching the new product, which is CE marked, immediately in the UK and plans to introduce it into select overseas markets as the relevant foreign language versions are completed over the course of the year. The software upgrade necessary to add the new product to the US version of the CardioQ-ODM+ requires separate regulatory clearance which the Company is pursuing with the manufacturer's support.

 

Heads of agreement

 

Deltex has signed heads of agreement with the manufacturer giving it exclusive rights to sell HD-ICG into critical care and surgical settings initially in a number of key Deltex markets including the UK, France, Scandinavia, Spain and Peru with mechanisms in place for additional territories in due course. Release in the USA is also intended to be on an exclusive basis subsequent to gaining regulatory approval.

 

The agreement is for an initial three years with roll-over provisions and secures Deltex's ability to support the modules for ten years after any termination.

 

Investor open day demonstration

 

HD-ICG will be demonstrated at the investor open day at Deltex's Chichester facility on Friday 5 May. Investors or potential investors wishing to attend this meeting who have not already registered should email investorinfo@deltexmedical.com.

 

Ewan Phillips, Deltex Medical's Chief Executive, commented:

 

"The addition of High Definition Impedance Cardiography to our monitoring platform is an exciting development. It gives us an easy to use non-invasive cardiac output monitoring technology which is broadly complementary to our exisiting ODM technology.

 

"Following the 2012 addition of Pulse Pressure Waveform Analysis to CardioQ-ODM+, we are now able to offer our customers all three of the leading advanced haemodynamic monitoring technologies on a single platform. This means clinicians can choose the most appropriate technology for their monitoring requirements across the whole hospital."

 

For further information, please contact:-

 

Deltex Medical Group plc

01243 774 837

investorinfo@deltexmedical.com

Nigel Keen, Chairman

Ewan Phillips, Chief Executive

Jonathan Shaw, Group Finance Director

Nominated Adviser & Broker

Arden Partners plc

020 7614 5900

Chris Hardie

 

Financial Public Relations

IFC Advisory

0203 053 8671

Tim Metcalfe

Graham Herring

Heather Armstrong

 

 

Notes for Editors

 

Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's ODM is the only technology to measure blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only company in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, ODM. Randomised, controlled trials using Doppler have demonstrated that early fluid management intervention will reduce post-operative complications, reduce intensive care admissions, and reduce the length of hospital stay.

 

Company goal

ODM is increasingly recognised as a standard of care for patients undergoing major surgery and in critical care. The broader clinical area of haemodynamic management of which ODM is a core constituent is also now becoming widely accepted as an important major new medical modality. Consequently, the Company's focus is on maximising value from the opportunities presented as enhanced haemodynamic management is adopted into routine clinical practice around the world.

 

The Company is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK, USA, Spain and Canada and through distribution arrangements in a further 30 countries.

 

There are over 3,400 monitors installed in hospitals around the world and around 700,000 patients have been treated to date using Deltex Medical's single patient disposable probes.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAUGUCCAUPMGQW
Date   Source Headline
3rd Sep 20097:00 amRNSInterim Results
3rd Aug 200911:13 amRNSHolding(s) in Company
29th Jul 20091:21 pmRNSCardioQ-ODM established as a gold standard
24th Jul 20094:03 pmRNSHolding(s) in Company
20th Jul 20097:00 amRNSTrading Statement
2nd Jul 200912:05 pmRNSDirector/PDMR Shareholding
30th Jun 20093:16 pmRNSExercise of Options
30th Jun 20093:12 pmRNSTotal Voting Rights
12th Jun 200910:28 amRNSExercise of options
12th Jun 20099:28 amRNSNon-Executive Directors' Shareholdings
12th Jun 20099:22 amRNSGrant of options
13th May 20091:54 pmRNSAGM Results
13th May 200911:00 amRNSChairman's statement to Annual General Meeting
24th Apr 20093:26 pmRNSAnnual Report and Accounts
3rd Apr 20099:22 amRNSDirectors' share dealings
30th Mar 20094:46 pmRNSDirectors' Share Dealings
4th Mar 20097:00 amRNSPreliminary Results
27th Feb 20097:00 amRNSFund Raising
12th Feb 200912:27 pmRNSResponse to NIHR report
22nd Jan 20097:00 amRNSChange of Adviser
22nd Jan 20097:00 amRNSPre-close update on the year ended 31 Dec 2008
3rd Dec 20089:20 amRNSRe Contract
21st Nov 20087:00 amRNSStatement Re CardioQ-ODM
11th Nov 200810:53 amRNSHolding(s) in Company
7th Nov 20087:00 amRNSInvestor Open Day
6th Nov 20089:00 amRNSResult of Spanish CardioQ-ODM Audit
1st Oct 20087:00 amRNSCardioQ-ODM in Keyhole Surgery
16th Sep 20087:00 amRNSInterim Results
15th Sep 20087:00 amRNSUS HTA on pulmonary artery catheters
3rd Sep 20087:00 amRNSCardioQ Update
20th Aug 20087:00 amRNSNHS National Technology Adopt
31st Jul 20088:29 amRNSTotal Voting Rights
8th Jul 20087:40 amRNSTrading Statement
1st Jul 20082:25 pmRNSDirector/PDMR Shareholding
30th Jun 20083:35 pmRNSTotal Voting Rights
30th Jun 20087:40 amRNSDirector/PDMR Shareholding
30th Jun 20087:30 amRNSDirector/PDMR Shareholding
30th Jun 20087:00 amRNSInterim Trial Results
26th Jun 20083:46 pmRNSIssue of Equity
24th Jun 200811:08 amRNSIssue of Equity
27th May 20084:00 pmRNSIssue of Equity
13th May 200811:50 amRNSResult of AGM
13th May 200811:50 amRNSResult of AGM
9th May 20089:22 amRNSHolding(s) in Company
8th May 20087:01 amRNSCardioQ-ODM Update
25th Apr 20089:07 amRNSClinical Paper
23rd Apr 20087:01 amRNSNext Generation of CardioQ
22nd Apr 200812:10 pmRNSHolding(s) in Company
18th Apr 20087:00 amRNSCompletion of Funding Package
15th Apr 20087:01 amRNSCardioQ update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.